Tauopathies

Subscribe to Selected New Research on Tauopathies

302 relevant articles (9 outcomes, 18 trials/studies) found for this Disease

Description: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.

Also Known As:

Tauopathy

Relationship Network

Disease Context: Research Results

Nervous System Diseases: 3414

Neurodegenerative Diseases: 7363

Tauopathies: 302

Alzheimer Disease: 25964

Progressive Supranuclear Palsy: 464

Related Diseases

1.	Tauopathies
2.	Parkinson Disease (Parkinson's Disease)
3.	Dementia (Dementias)
4.	Neurodegenerative Diseases (Neurodegenerative Disease)
5.	Alzheimer Disease (Alzheimer's Disease)

Experts

1.	Trojanowski, John Q: 7 articles (06/2008 - 06/2002)
2.	Lee, Virginia M-Y: 7 articles (06/2008 - 06/2002)
3.	Ferrer, I: 5 articles (04/2006 - 01/2001)
4.	Puig, B: 4 articles (04/2006 - 01/2001)
5.	Uryu, Kunihiro: 3 articles (06/2008 - 06/2002)
6.	Dickson, Dennis: 2 articles (07/2008 - 05/2005)
7.	Lewis, Jada: 2 articles (07/2008 - 05/2005)
8.	Miller, Bruce L: 2 articles (06/2008 - 06/2002)
9.	Forman, Mark S: 2 articles (06/2008 - 01/2004)
10.	Grossman, Murray: 2 articles (06/2008 - 06/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Tauopathies:

1.	Proteins (Proteins, Gene)IBA 05/01/2005 - "Some proteins are quite useful for discovering the molecular mechanisms of tauopathies and may be helpful for diagnosis and of treatment tauopathies." 05/01/2005 - "Comparative proteomic analysis of brain proteins was employed to study 4 patients with tauopathies as compared with 4 controls" 07/01/2008 - "METHOD: Two-dimensional gel electrophoresis (2DE) was applied to separate the total proteins of temporal lobe obtained at autopsy from four tauopathies cases and four aged subjects without clinical or pathologic involvement of nervous system" 07/01/2008 - "OBJECTIVES: To identify differentially expressed proteins between tauopathies cases and controls and to explore molecular mechanisms of tauopathies" 05/29/2007 - "Inhibition of Hsp90 in cellular and mouse models of tauopathies leads to a reduction of the pathogenic activity of these proteins and results in elimination of aggregated Tau" Order ALL the reference details at left...
2.	alpha-SynucleinIBA 07/01/2000 - "Thus, the present study suggests that a common mechanism may govern aggregation of alpha-synuclein and tau in the amygdala, and that aggregation of alpha-synuclein may play some role in the neurodegenerative process of a tauopathy (i.e" 08/01/2004 - "Now we can see a striking resemblance between alpha-synuclein and tau: both have the same physiological function and pathological features, making abnormal structures in diseased brains known as synucleinopathies and tauopathies" 03/01/2004 - "Thus, the ability of tau and alpha-synuclein to affect each other directly or indirectly might contribute to the overlap in the clinical and pathological features of tauopathies and synucleinopathies." 08/01/2005 - "Deposits of tau and alpha-synuclein are hallmarks of distinct neurodegenerative diseases: tauopathies and alpha-synucleinopathies" 01/01/2000 - "Familial parkinsonism with dementia, linked to chromosome 17 (frontotemporal dementia with Parkinsonism (FTDP-17), and other tauopathies pathologically resembling PD plus AD, are often related to mutations of the tau gene, whereas familial PD with alpha-synuclein and Parkin mutations usually show no cognitive impairment" Order ALL the reference details at left...
3.	UbiquitinIBA 08/01/2008 - "It may help to distinguish those cases of FTLD with ubiquitin/TDP-43 pathology in their brains from those with tauopathy" 04/01/2008 - "Several other kindreds with FTDP had been linked to chromosome 17, but they had ubiquitin-positive inclusions rather than tauopathy pathology and no mutations in MAPT" 03/01/2008 - "Here we present evidence to show that S6b coexists with a reporter for proteasomal dysfunction (ubiquitin(+1)), and we conclude that S6b transcript up-regulation and the dysfunction in tauopathies may be functionally related." 12/01/2003 - "Ubiquitin-negative mini-pick-like bodies in the dentate gyrus in p301l tauopathy." 01/01/2003 - "Immunohistochemical analyses demonstrated that tauopathy with phosphorylated tau accumulation in the Pick bodies in PiD cases, while aPiD cases showed ubiquitinopathy with ubiquitin accumulation in the intraneuronal and dendritic inclusions" Order ALL the reference details at left...
4.	Carrier Proteins (Binding Protein)IBA 01/04/2005 - "We tested the hypothesis that microtubule (MT)-binding drugs could be therapeutically beneficial in tauopathies by functionally substituting for the MT-binding protein tau, which is sequestered into inclusions of human tauopathies and transgenic mouse models thereof" 03/29/2006 - "The microtubule binding protein tau is implicated in neurodegenerative tauopathies, including frontotemporal dementia (FTD) with Parkinsonism caused by diverse mutations in the tau gene" 07/20/2001 - "Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies." 07/01/2008 - "Taken together, the identification of a novel calcium-binding protein associated with tau protein in terminally ill tauopathy mouse model and its confirmation in human brain lysate suggests that this association may play an important physiological and/or pathological role." 07/01/2008 - "A novel calcium-binding protein is associated with tau proteins in tauopathy." Order ALL the reference details at left...
5.	Valproic Acid (Valproate, Semisodium)FDA LinkGeneric 12/01/2002 - "Neuroprotective properties of valproate: potential benefit for AD and tauopathies." 12/01/2002 - "In this article we present the rationale for testing the neuroprotective potential of valproate experimentally in mouse models of tauopathy and in a clinical trial of patients with AD who lack psychopathology at baseline" Order ALL the reference details at left...
6.	Niacinamide (Nicotinamide)FDA Link 11/05/2008 - "These preclinical findings suggest that oral nicotinamide may represent a safe treatment for AD and other tauopathies, and that phosphorylation of tau at Thr231 may regulate tau stability." Order ALL the reference details at left...
7.	Memantine (Namenda)FDA Link 05/21/2004 - "These findings show (1) that memantine inhibits and reverses the PP-2A inhibition-induced abnormal hyperphosphorylation of tau/neurofibrillary degeneration and (2) that this drug might be useful for the treatment of AD and related tauopathies." Order ALL the reference details at left...
8.	tau Proteins (tau Protein)IBA 10/01/2006 - "Findings in these tau transgenic mice support the notion that impairments of tau proteins are causally related to tauopathies, while studies on crossbred mice have indicated initiation and promotion of tau-positive neuropathologies by crosstalk among several pathogenic molecules" 01/13/2006 - "We generated several cell models of tauopathy in order to study the mechanisms of neurodegeneration in diseases involving abnormal changes of tau protein" 11/01/2008 - "The 17q21.3 region includes the gene of microtubule-associated protein tau, and this result might imply higher sensitivity to H1 haplotype-related multifactorial tauopathies among Gypsies." 07/20/2008 - "The neurodegenerative tauopathies are typified by the intracellular aggregation of hyperphosphorylated microtubule-associated protein tau (MAPT) and the dysfunction and death of affected neurons" 07/01/2008 - "These diseases are summarized as tauopathies, because neurofibrillary tangles are composed of intracellular aggregates of the microtubule-associated protein tau" Order ALL the reference details at left...
9.	Amyloid (Amyloid Fibrils)IBA 12/01/2007 - "Tau and beta-amyloid-related pathologies were more significantly recognized in tauopathies/AD compared to non-tauopathies/controls, and these results were comparable to the assessment of the whole brain sections" 04/10/2006 - "Since Sp1 binding sites are present in the promoters of several genes involved in amyloid and tau, and Sp1 is regulated by oxidative stress, the present findings suggest that Sp1 deposition in hyper-phosphorylated tau deposits may have functional consequences in the pathology of AD and other tauopathies." 03/01/2006 - "We wanted to determine if this overlap of lesions is statistical, as a result of the late onset of both diseases, or results from a specific physiopathological synergy between synucleinopathy and either tauopathy or amyloid pathology" 05/01/2004 - "We report here a novel PS1 mutation in a patient with Pick-type tauopathy in the absence of extracellular beta-amyloid deposits" 04/01/2000 - "In a subset of Abeta40-positive plaques, degenerating neurites--without tauopathy--and/or amyloid cores were observed" Order ALL the reference details at left...
10.	Protein Isoforms (Isoforms)IBA 10/01/2006 - "Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies." 07/01/2008 - "In several tauopathies there is a shift toward four-repeat tau isoforms, and interference with the splicing machinery to decrease four-repeat splicing might be another therapeutic option." 08/01/2005 - "Common to both these two tauopathies is that isoforms of four-repeat tau due to splicing of exon 10 define the tau filamentous aggregates" 12/01/2004 - "Such transgenic overexpression of tau in multiple isoforms facilitated the assembly of filamentous tau aggregates that exhibit immunoreactivities, physicochemical properties, and ultrastructural attributes reminiscent of those found in human tauopathies" 04/15/2004 - "We have analyzed the expression of three-repeat (3R) and four-repeat (4R) tau isoforms in brains with familial and sporadic tauopathies" Order ALL the reference details at left...

Therapies and Procedures

1.	Therapeutics 11/01/2007 - "The molecular basis of chaperone-mediated protection against neurodegeneration might lead to the development of therapeutics for tauopathies" 09/01/2006 - "All these morphological and biochemical data demonstrate that there is a synergistic contribution of both types of tau modifications and that the potential of GSK-3 inhibitors for AD therapeutics also extends to tauopathies caused by point mutations in tau gene." Order ALL the reference details at left...
2.	Immunotherapy 10/01/2006 - "CONCLUSIONS: These results provide a link between tau autoimmunity and tauopathy-like abnormalities and indicate potential dangers of using tau for immunotherapy" 10/01/2008 - "Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies." Order ALL the reference details at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>